BIOCYTOGEN PHARMA. H YC1 (F:I54) — Market Cap & Net Worth
Market Cap & Net Worth: BIOCYTOGEN PHARMA. H YC1 (I54)
BIOCYTOGEN PHARMA. H YC1 (F:I54) has a market capitalization of $715.43 Million (€611.95 Million) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #10296 globally and #1232 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCYTOGEN PHARMA. H YC1's stock price €5.70 by its total outstanding shares 107359562 (107.36 Million). See reinvestment intensity of BIOCYTOGEN PHARMA. H YC1 to understand how much of operating cash flow is reinvested back into capital assets.
BIOCYTOGEN PHARMA. H YC1 Market Cap History: 2022 to 2026
BIOCYTOGEN PHARMA. H YC1's market capitalization history from 2022 to 2026. Data shows growth from $371.52 Million to $715.43 Million (17.32% CAGR).
BIOCYTOGEN PHARMA. H YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCYTOGEN PHARMA. H YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.34x
BIOCYTOGEN PHARMA. H YC1's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.72x
BIOCYTOGEN PHARMA. H YC1's market cap is 2.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $371.52 Million | $533.88 Million | -$601.95 Million | 0.70x | N/A |
| 2023 | $215.89 Million | $716.91 Million | -$382.95 Million | 0.30x | N/A |
| 2024 | $112.96 Million | $980.45 Million | $33.54 Million | 0.12x | 3.37x |
| 2025 | $470.68 Million | $1.38 Billion | $173.20 Million | 0.34x | 2.72x |
Competitor Companies of I54 by Market Capitalization
Companies near BIOCYTOGEN PHARMA. H YC1 in the global market cap rankings as of August 4, 2026.
Key companies related to BIOCYTOGEN PHARMA. H YC1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
BIOCYTOGEN PHARMA. H YC1 Historical Marketcap From 2022 to 2026
Between 2022 and today, BIOCYTOGEN PHARMA. H YC1's market cap moved from $371.52 Million to $ 715.43 Million, with a yearly change of 17.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €715.43 Million | +52.00% |
| 2025 | €470.68 Million | +316.67% |
| 2024 | €112.96 Million | -47.67% |
| 2023 | €215.89 Million | -41.89% |
| 2022 | €371.52 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of BIOCYTOGEN PHARMA. H YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $715.43 Million USD |
| MoneyControl | $715.43 Million USD |
| MarketWatch | $715.43 Million USD |
| marketcap.company | $715.43 Million USD |
| Reuters | $715.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more